Confidence in Covid-19 vaccines is growing, with people’s willingness to have the shots increasing as they are rolled out across the world and concerns about possible side effects are fading, a 14-country survey showed on March 5.
COVAX will deliver 237 million doses of AstraZeneca’s Covid-19 shot to 142 countries by the end of May as the World Health Organization-backed program steps up the global roll-out of its vaccine supplies.
The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing Covid-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.
Many health experts believe that the Covid-19 vaccine candidate NVX-CoV237 from Novavax offers potential advantages over competitors including Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca-Oxford.
Drug developer Novavax Inc. completed enrolling 30,000 volunteers in a late-stage study of the company’s Covid-19 vaccine in the United States and Mexico.
As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.
The World Health Organization (WHO) on Feb. 15 listed AstraZeneca and Oxford University’s Covid-19 vaccine for emergency use, widening access to the relatively inexpensive shot in the developing world.
In a historical move, healthcare investor giant Deerfield Management entered a second partnership with one of its academic collaborators, investing up to $130 million over the next ten years into Dana-Farber Cancer Institute to advance the development of new therapeutics and diagnostic tools for cancer patients.
The worldwide coronavirus death toll surpassed 2 million on Jan. 15, according to a Reuters tally, as nations around the world are trying to procure multiple vaccines and detect new Covid-19 variants.
The United States lost more than 22,000 lives to Covid-19 for the week ended Jan. 10, setting a record for the second week in a row, as new cases also hit a weekly high.